Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Perfusion
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dellora, C.
Right arrow Articles by Parodi, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dellora, C.
Right arrow Articles by Parodi, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

C1-esterase inhibitor following cardiopulmonary bypass: evaluation of coagulation parameters - a preliminary report

Carlo Dellora

Departments of Chemical and Clinical Research, Anaesthesia and Intensive Care, and Heart Surgery, Ospedale Maggiore, Novara, Italy

Paola Minola

Departments of Chemical and Clinical Research, Anaesthesia and Intensive Care, and Heart Surgery, Ospedale Maggiore, Novara, Italy

Filippo Parodi

Departments of Chemical and Clinical Research, Anaesthesia and Intensive Care, and Heart Surgery, Ospedale Maggiore, Novara, Italy

This study was designed to evaluate the effects of C1-esterase inhibitor (C1-INH) on haemostasis and blood loss in routine cardiopulmonary bypass (CPB). To determine whether or not C1-INH reduces blood loss or transfusion requirements after routine CPB, we randomized 20 patients to receive double-blind either C1-INH (15 IU/kg over 10 minutes intravenously) or placebo following heparin administration. The two groups were similar in age, sex, prior salicylate use and time on CPB.

At 30 minutes from the beginning of CPB and postprotamine, factor XII, factor XI, C1-INH and prekallikrein activity were significantly higher (p < 0.05) than in the placebo group. No manifestations of hypercoagulability were seen in either group. Despite this haemostatic effect, patients treated with C1-INH had similar postoperative blood loss to the placebo group and similar blood transfusion requirements.

We conclude that routine use of C1-INH in CPB is unwarranted.

Perfusion, Vol. 7, No. 3, 195-199 (1992)
DOI: 10.1177/026765919200700303
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?